- The National Institute for Health and Care Excellence (Nice) has rejected two Alzheimer’s drugs, Donanemab and Lecanemab, for use on the NHS.
- Nice determined that the drugs offer only “modest benefits at best,” delaying disease progression by four to six months in early stages.
- The decision was based on the drugs' limited benefits not justifying their high cost, estimated to be between £500 million and £1 billion annually for the NHS.
- Donanemab and Lecanemab are targeted antibody drugs that work by clearing amyloid protein buildup in the brain to slow cognitive decline.
- Scientists and doctors remain divided on the drugs' clinical significance, with some highlighting their potential while others raise concerns about the small benefits and serious side effects observed in trials.
IN FULL